CareDx, Inc (CDNA) Insider Trading Activity

NASDAQ$78.56
Market Cap
$4.13B
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
470 of 846
Rank in Industry
18 of 38

CDNA Insider Trading Activity

CDNA Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$13,308,479
22
100

Related Transactions

TORRES ARTHUR Adirector
0
$0
2
$214,676
$-214,676
Novack Jeffrey AdamSecretary and General Counsel
0
$0
5
$452,744
$-452,744
COURNOYER CHRISTINEdirector
0
$0
1
$750,973
$-750,973
Bickerstaff Georgedirector
0
$0
1
$925,700
$-925,700
Valantine Hannahdirector
0
$0
2
$1.32M
$-1.32M
Goldberg Michaeldirector
0
$0
1
$2.1M
$-2.1M
Hanna John Walter JRPresident and CEO
0
$0
10
$7.54M
$-7.54M

About CareDx, Inc

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

Insider Activity of CareDx, Inc

Over the last 12 months, insiders at CareDx, Inc have bought $0 and sold $13.31M worth of CareDx, Inc stock.

On average, over the past 5 years, insiders at CareDx, Inc have bought $211,694 and sold $5.25M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,000 shares for transaction amount of $211,694 was made by Dhingra Ankur (Chief Financial Officer) on 2021‑11‑24.

List of Insider Buy and Sell Transactions, CareDx, Inc

2026-08-05SaleBickerstaff Georgedirector
20,000
0.0393%
$46.28
$925,700
+21.78%
2026-08-05SaleNovack Jeffrey AdamSecretary and General Counsel
2,688
0.0053%
$46.26
$124,349
+21.78%
2026-08-04SaleGoldberg Michaeldirector
44,700
0.0863%
$47.06
$2.1M
+15.37%
2026-08-04SaleCOURNOYER CHRISTINEdirector
16,000
0.0308%
$46.94
$750,973
+15.37%
2026-07-16SaleHanna John Walter JRPresident and CEO
118,000
0.214%
$37.79
$4.46M
+29.81%
2026-07-16SaleValantine Hannahdirector
28,779
0.0499%
$36.15
$1.04M
+29.81%
2026-06-29SaleHanna John Walter JRPresident and CEO
39,900
0.0771%
$29.24
$1.17M
+71.40%
2026-06-26SaleHanna John Walter JRPresident and CEO
100
0.0002%
$29.00
$2,900
+73.87%
2026-06-15SaleHanna John Walter JRPresident and CEO
17,683
0.0342%
$24.03
$424,877
+106.77%
2026-06-15SaleValantine Hannahdirector
12,103
0.0225%
$23.11
$279,728
+106.77%
2026-06-11SaleHanna John Walter JRPresident and CEO
21,998
0.0432%
$24.02
$528,443
+109.64%
2026-06-04SaleHanna John Walter JRPresident and CEO
4,835
0.0097%
$24.00
$116,045
+108.61%
2026-05-15SaleTORRES ARTHUR Adirector
6,484
0.0125%
$19.89
$128,978
+135.70%
2026-05-14SaleTORRES ARTHUR Adirector
4,086
0.0081%
$20.97
$85,698
+129.53%
2026-05-05SaleNovack Jeffrey AdamSecretary and General Counsel
2,688
0.0052%
$20.68
$55,581
+124.06%
2026-04-16SaleHanna John Walter JRPresident and CEO
10,282
0.0188%
$21.12
$217,156
+78.57%
2026-02-03SaleNovack Jeffrey AdamSecretary and General Counsel
4,441
0.0086%
$20.56
$91,286
+29.20%
2026-01-22SaleHanna John Walter JRPresident and CEO
19,280
0.0377%
$21.16
$408,023
+13.56%
2026-01-21SaleHanna John Walter JRPresident and CEO
200
0.0004%
$21.00
$4,200
+13.59%
2026-01-15SaleHanna John Walter JRPresident and CEO
10,156
0.0202%
$21.05
$213,804
+14.10%
Total: 258
*Gray background shows transactions not older than one year

Insider Historical Profitability

58.32%
Hanna John Walter JRPresident and CEO
653448
1.2436%
$51.33M010
Bickerstaff Georgedirector
134061
0.2551%
$10.53M07
Novack Jeffrey AdamSecretary and General Counsel
106075
0.2019%
$8.33M012
Goldberg Michaeldirector
61738
0.1175%
$4.85M113
<0.0001%
COURNOYER CHRISTINEdirector
42943
0.0817%
$3.37M03
TORRES ARTHUR Adirector
38665
0.0736%
$3.04M12
<0.0001%
Valantine Hannahdirector
36686
0.0698%
$2.88M03
TPG Group Holdings (SBS) Advisors, Inc.10 percent owner
1075090
2.0461%
$84.46M10
<0.0001%
BYERS BROOK H
751174
1.4296%
$59.01M10
<0.0001%
KLEINER PERKINS CAUFIELD & BYERS X A LP10 percent owner
751174
1.4296%
$59.01M10
<0.0001%
Seeto ReginaldSee Remarks
479164
0.912%
$37.64M034
Jain AbhishekChief Financial Officer
337418
0.6422%
$26.51M01
Maag Peterdirector
308846
0.5878%
$24.26M458
+57.09%
Johnson Alexander LSee Remarks
284983
0.5424%
$22.39M03
Gagnon Neil10 percent owner
107940
0.2054%
$8.48M481
+71.45%
Bell Michael BrianChief Financial Officer
103343
0.1967%
$8.12M110
+288.89%
Nelles Mitchell JChief Operating Officer
85160
0.1621%
$6.69M12
<0.0001%
HAGSTROM WILLIAM Adirector
53979
0.1027%
$4.24M08
SNYDERMAN RALPHdirector
51015
0.0971%
$4.01M05
Yee James PChief Medical Officer
42045
0.08%
$3.3M05
King SashaChief Marketing Officer
40139
0.0764%
$3.15M016
Whitson ToddChief Commercial Officer
10000
0.019%
$785,600.0010
<0.0001%
LUDLUM KENChief Financial officer
5000
0.0095%
$392,800.0010
<0.0001%
Dhingra AnkurChief Financial Officer
5000
0.0095%
$392,800.0010
<0.0001%
Colon Grace
4864
0.0093%
$382,115.8403
*Gray background shows insiders who have made transactions during last year

CDNA Institutional Investors: Active Positions

Increased Positions105+49.3%7M+12.88%
Decreased Positions90-42.25%7M-13.41%
New Positions44New2MNew
Sold Out Positions27Sold Out1MSold Out
Total Postitions228+7.04%53M-0.53%

CDNA Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Blackrock, Inc.$91,239.009.35%4.77M+108,998+2.34%2025-09-30
Vanguard Group Inc$71,769.007.35%3.75M-1M-23.64%2025-09-30
Bamco Inc /Ny/$60,390.006.19%3.16M+719,523+29.54%2025-09-30
State Street Corp$49,122.005.03%2.57M+386,304+17.72%2025-09-30
Ophir Asset Management Pty Ltd$42,069.004.31%2.2M+304,953+16.11%2025-09-30
Deerfield Management Company, L.P.$41,936.004.3%2.19M+2MNew2025-09-30
Braidwell Lp$41,778.004.28%2.18M+2MNew2025-09-30
Ark Investment Management Llc$41,546.004.26%2.17M+70,468+3.35%2025-09-30
Sumitomo Mitsui Trust Group, Inc.$33,305.003.41%1.74M+503,136+40.68%2025-09-30
Amova Asset Management Americas, Inc.$33,305.003.41%1.74M+504,473+40.83%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.